Overview

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of ELIGARD 22.5mg in the treatment of subjects with prostate cancer.
Phase:
Phase 4
Details
Lead Sponsor:
HanAll BioPharma Co., Ltd.
Treatments:
Leuprolide